[HTML][HTML] Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
EA Bryushkova, VD Skatova, ZY Mutovina… - PloS one, 2022 - journals.plos.org
Objective The aim of the study was to assess inflammatory markers and clinical outcomes in
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
EA Bryushkova, VD Skatova, ZY Mutovina… - Plos one, 2022 - europepmc.org
Objective The aim of the study was to assess inflammatory markers and clinical outcomes in
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
EA Bryushkova, VD Skatova, ZY Mutovina… - PLoS …, 2022 - search.ebscohost.com
Objective: The aim of the study was to assess inflammatory markers and clinical outcomes in
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: an observational study.
EA Bryushkova, VD Skatova, ZY Mutovina… - 2022 - cabidigitallibrary.org
Objective: The aim of the study was to assess inflammatory markers and clinical outcomes in
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
[HTML][HTML] Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
EA Bryushkova, VD Skatova, ZY Mutovina… - PLoS ONE, 2022 - ncbi.nlm.nih.gov
Objective The aim of the study was to assess inflammatory markers and clinical outcomes in
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
EA Bryushkova, VD Skatova, ZY Mutovina… - PLoS …, 2022 - ui.adsabs.harvard.edu
Objective The aim of the study was to assess inflammatory markers and clinical outcomes in
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
EA Bryushkova, VD Skatova, ZY Mutovina… - PloS …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective The aim of the study was to assess inflammatory markers and clinical outcomes in
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …
adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a …